Canada Markets closed

Akero Therapeutics, Inc. (0K4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
26.60-0.20 (-0.75%)
At close: 08:00AM CEST

Yahoo Finance will soon be upgrading our Conversations message board platform to provide a better experience for our users. Only comments published since April 21, 2021 will be visible on Yahoo Finance after the upgrade. If you wish to download and save any of your older comments, please submit a request via the Privacy Dashboard by no later than Sept. 30.

Sign in to post a message.
  • S
    ScorpionLeather
    AKRO investors should also consider another NASH candidate that hasn't run up yet and trading at an extreme value price right now, Galectin Therapeutics (GALT). It is positioned to possibly be the first to market for advanced NASH cirrhosis, and same compound is promising for cancer immunotherapy as well (multiple shots on goal). There is heavy inside buying, the CEO takes 80% pay in stock and the billionaire Chairman recently invested another $60 million of his own money. This is what was published in the scientific journals about GALT recently:

    -----

    "Overall, the clinical success of Belapectin indicates a promising path for the continued clinical development of Belapectin in compensatory NASH cirrhosis, which could make it the first anti-fibrosis drug candidate to win approval from NASH regulators."

    New Drugs for Hepatic Fibrosis, Shan et al. 13 June 2022.

    -----

    Macrophage functional diversity in NAFLD — more than inflammation
    Journal Nature - 09 May 2022

    "Galectin 3 is mainly expressed by macrophages and its inhibition has beneficial effects on fibrosis development. The inhibitor belapectin (GR- MD-02) was tested in clinical trials and was effective in reducing portal hypertension and fibrosis. Another trial is currently ongoing to confirm these results."

    -----

    Current and emerging therapies for the management of cirrhosis and its complications
    (Authored by world’s top liver KOLs)
    Wiley AP&T - 02 March 2022
    “ A randomised phase 2b trial of belapectin, … , belapectin reduced hepatic venous pressure gradient and improved fibrosis”
  • R
    Richard
    offering at $12 and change...glad I only bought 1 share
  • R
    Randy
    to all the shorts in AKRO, you got what you deserve today, congratulations to all the longs.
  • M
    Mark
    Pfizer wants to buy the whole company IMO.
  • D
    DD
    making no revenue and its only phase 2- it will take 3-5 years before it can make any penny- this will be $15 in 2 weeks.
  • P
    Penny
    I'm short !
  • g
    gfdne1997
    short if you can ... tomorrow is another day.
  • B
    Bella
    I have approximately 500k in a bag of crypto, I can send a key for 25k to see what she can do and then we will talk about the rest. Tell me we’re to send initial key
  • T
    Tony
    People, you've just doubled your money. Don't be greedy, take some gains and be happy!!!
  • P
    Penny
    1 minute 3 minute 5 minute 200 EMA broken. Next up 15 minute support at around 23. See ya there
  • s
    sam
    They just announce $175 million stock offering.Will that take away some of today’s gains?
  • s
    stk
    40$++ possible?
  • T
    Tristan
    I'm a newbie in crybto and holding some cryptocurrencies in my wallet but am scared i'm to lose my funds due to the recent crash😢
  • R
    Richard Carter
    Hahahaha, burn shorties! Burnnnnnnnnn
  • K
    K P
    $AKRO
    Above $100, Other NASH company was trading around $300
  • G
    GEORGE
    Nothing but spammers on this MB.
  • J
    Jorge
    10 to 15% down tomorrow after large secondary offering.
  • P
    Penny
    Monday Monday Monday!
  • T
    Tom
    This will go to $40 soon due to potential take over. These are the cheap ones. Buy!
  • F
    F
    Evercore raised TP to 50. Being long was painful over the last months but now the party started:).